Tools | Bookmark & Share | Make MrWhy My Homepage
MrWhy.com
Go
MrWhy.com » Videos » Amgen Sees Fractional Gains After Failure of Cancer Drug Stu
Amgen Sees Fractional Gains After Failure of Cancer Drug Stu
Amgen Sees Fractional Gains After Failure of Cancer Drug Stu
Report
Amgen Sees Fractional Gains After Failure of Cancer Drug Stu
Amgen Inc. (AMGN) opened higher and is holding fractional gain in early trader after announcing that a potential cancer treatment it’s developing with Takeda Pharmaceutical Company Ltd. failed to meet its key goal in a study. The drug, motesanib, was tested on lung cancer patients in a late-stage study, but failed to improve overall survival rates for patients with non-squamous non-small cell lung cancer.
Channel: Voxant Newsroom
Category: Business
Video Length: 0
Date Found: March 30, 2011
Date Produced: March 30, 2011
View Count: 0
 
MrWhy.com Special Offers
1
2
3
4
5
 
About Us: About MrWhy.com | Advertise on MrWhy.com | Contact MrWhy.com | Privacy Policy | MrWhy.com Partners
Answers: Questions and Answers | Browse by Category
Comparison Shopping: Comparison Shopping | Browse by Category | Top Searches
Shop eBay: Shop eBay | Browse by Category
Shop Amazon: Shop Amazon | Browse by Category
Videos: Video Search | Browse by Category
Web Search: Web Search | Browse by Searches
Copyright © 2011 MrWhy.com. All rights reserved.